A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
Clinical trial NCT04898634 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04898634
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-13
- Primary completion
- 2027-03-31
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.